NCT05489744View on ClinicalTrials.gov

Human Mass Balance and Biotransformation Study of [14C]Afuresertib

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 6, 2022

Primary Completion Date

October 21, 2022

Study Completion Date

October 21, 2022

Conditions
Healthy Volunteer
Interventions
DRUG

[14C]Afuresertib

Suspension containing approximately 125 mg of Afuresertib (containing 150 µCi of \[14C\]Afuresertib) is administered orally on an empty stomach, with approximately 240 mL of water for suspending and drug taking.

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Laekna Limited

INDUSTRY